Abcam Provides FY24 Guidance & Confirms FY23 Outlook

Abcam PLC ABCM provided an FY24 outlook and reaffirmed FY23 guidance

FY24 Guidance: The company expects reported revenue of approximately £475 million to £525 million, representing a constant exchange rate (CER) CAGR of 11.3% to 13.4% and organic CAGR of 10.0% to 12.1% vs. FY19.

ABCM projects adjusted operating profit margins in the 32% to 36% range and adjusted EBITDA margins of 42% and 46%, including the ongoing cost improvement initiatives announced last month.

Notably, the company disclosed incremental cost refinement initiatives earlier last month, expecting to reduce annualized run rate operating expenses by over £15 million by 2024

The company anticipates reported ROCE of 14% to 18% and ROCE, excluding the impact of BioVision, of 15% to 19% in FY24, with incremental value expected in the coming years.

FY23 Outlook Reaffirmed: Abcam continues to expect revenues of around £420 million to £440 million, representing CER growth of 15% to 20%.

Also, the company reiterated its outlook for an adjusted operating profit margin of 27% to 28% and adjusted EBITDA margins in the 36.5% to 37% range. 

Last week, Abcam announced that its Board of Directors unanimously decided to initiate a process to explore strategic alternatives.

Also ReadAbcam Downgrade: Analyst Trims Expectations Amid Activist Investor Engagement and Potential Bid Anticipation

Price Action: ABCM shares closed lower by 2.09% at $22.49 on Monday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: EquitiesMid CapNewsGuidanceHealth CareMarketsGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!